Amolyt Pharma Email Format

Biotechnology ResearchAuvergne-Rhône-Alpes, France11-50 Employees

Amolyt Pharma is a France-based biotechnology company focused on developing therapies for rare endocrine and related diseases. Its portfolio includes eneboparatide (AZP-3601), a long-acting activator of the PTH1 receptor being explored for hypoparathyroidism, and AZP-3813, a peptide that antagonizes the growth hormone receptor with potential applications in acromegaly. The company relies on its team’s specialist expertise in endocrinology to pursue life-changing treatments for patients with limited options. Based in Écully, in the Auvergne-Rhône-Alpes region, Amolyt Pharma operates as a small to mid-sized organization. Amolyt Pharma aims to broaden its portfolio by leveraging a global network in endocrinology and the support of international investors. In 2024, AstraZeneca announced its acquisition of Amolyt Pharma, reflecting a strategic move within the field of rare endocrine disease therapies.

Get verified Amolyt Pharma emails free

Company overview Employee directory